These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-001213-34 Double-blind, double-dummy, randomized, multicentre study to compare the efficacy and safety of oral budesonide (9 mg) and oral mesalazine (4.5 g) in moderately active Crohn’s disease patients 2008-05-08 due-trials
Reported results 2004-001216-31 Double-blind, double-dummy, randomised, multicentre, comparative study of the efficacy and tolerability of once daily 3.0 g mesalazine granules versus three times daily 1.0 g mesalazine granules in pa... 2006-06-15 due-trials
Reported results 2004-001218-15 Double-blind, double-dummy, randomised, multicentre, 12-months, comparative study of the efficacy and tolerability of once daily 3.0 g mesalazine granules versus once daily 1.5 g mesalazine granules v... 2007-04-27 due-trials
Reported results 2004-005018-35 Randomized, single-blind, multicentre study to compare the efficacy and safety of once daily 1 g mesalazine suppositories versus three times daily 0.5 g mesalazine suppositories in patients with acute... 2007-06-06 due-trials
Reported results 2005-002754-22 An open, randomized, multicentre phase II pilot study to evaluate the efficacy of budesonide 3 mg effervescent tablet in patients with resistant oral chronic GvHD using different application durations... 2010-04-22 due-trials
Ongoing 2005-005919-24 Randomized, multicenter, double blind, placebo controlled trial, for the evaluation of the efficacy and tolerability of ursodeoxycholic acid on the dissolution of cholesterol gallstones (<15mm) after ... not-yet-due
Reported results 2006-000720-13 Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s d... 2014-02-18 due-trials
Exempt 2006-001046-13 Pharmacokinetic interaction study between budesonide and metronidazole in healthy volunteers not-yet-due
Reported results 2006-003712-22 Pharmacokinetics of UDCA in serum and bile in patients with early stage PBC (stage I-III) and in healthy volunteers 2009-11-25 due-trials
Reported results 2006-004159-39 Double-blind, double-dummy, randomised, place-controlled, mutli-centre phase III clinical study on the efficacy and tolerability on budesonide capsules vs. mesalazine granules vs. placebo for patients... 2011-06-21 due-trials
Reported results 2006-005377-22 Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with 9 mg budesonide or 3 g mesalazine in patien... 2008-08-07 due-trials
Reported results 2006-006393-14 Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypertens... 2012-10-31 due-trials
Reported results 2007-000680-22 Double-blind, randomized, placebo-controlled, parallel group, multi-centre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevention of recurrence... 2011-11-15 due-trials
Reported results 2007-001315-31 Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with... 2013-03-12 due-trials
Reported results 2007-002082-13 Randomised, double-blind, placebo-controlled, multicentre, comparative phase II pilot study on the efficacy and tolerability of an 8-week rectal treatment with 2 mg budesonide or placebo for the preve... 2011-08-22 due-trials
Reported results 2007-004040-70 Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsules... 2015-10-19 due-trials
Reported results 2008-001524-31 Double-blind, double-dummy, randomized, crossover, multicentre phase IV clinical study comparing the effect of Ursofalk® 500 mg tablets od versus Ursofalk® 250 mg capsules od on liver enzyme parameter... 2010-07-14 due-trials
Reported results 2008-004562-10 Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients wit... 2015-08-24 due-trials
Reported results 2008-005994-36 Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in p... 2017-01-16 due-trials
Reported results 2008-006957-42 Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three... 2012-05-10 due-trials
Reported results Terminated 2009-015158-39 Double-blind, dose-response, randomised, placebo-controlled, parallel group, multicentre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevention... 2013-01-29 due-trials
Reported results 2009-016692-29 Double-blind, double-dummy, randomized, placebo-controlled, phase IIa study on the efficacy and tolerability of a 14-day treatment with budesonide effervescent tablets vs. viscous budesonide suspensio... 2013-04-08 due-trials
Reported results 2011-002754-31 Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis 2015-10-22 due-trials
Reported results 2012-001830-32 Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine versus... 2014-10-06 due-trials
Reported results 2012-003300-13 A randomised, double-blind, double-dummy, multi-centre, comparative parallel-group study to evaluate the efficacy of oral Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. placeb... 2017-04-18 due-trials
Reported results 2012-003362-41 Randomized, double-blind, multicentre study to compare the efficacy and safety of two different dosages of a novel budesonide suppository versus a mesalazine suppository versus a combination therapy o... 2015-07-29 due-trials
Reported results 2012-003702-27 Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 12-weeks add-on treatment with LT-02 (gastro-resistant phosphatidylcholine granules... 2017-10-13 due-trials
Reported results 2013-001205-84 Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 48-weeks treatment with gastro-resistant phosphatidylcholine (LT-02) versus placebo... 2018-10-05 due-trials
Reported results 2013-001912-31 Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis 2020-01-13 due-trials
Reported results 2013-004605-38 Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of non-alcoholic fatty liver disea... 2016-09-20 due-trials
Reported results 2014-001484-12 Double-blind, randomized, placebo-controlled, phase III trial on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathologi... 2016-10-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-001485-99 Double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for mainte... 2020-12-11 bad-data
Reported results 2014-005635-14 Open-label, multi-centre, proof of concept phase IIa clinical trial on the efficacy and tolerability of an 8 week oral treatment with once daily 9 mg budesonide in patients with active ulcerative coli... 2017-02-20 due-trials
Reported results 2016-001921-15 Randomised, double-blind, double-dummy, multicentre study to compare the efficacy and safety of once daily novel 4 mg budesonide suppository versus once daily 2 mg budesonide foam in patients with acu... 2020-03-30 due-trials
Ongoing 2016-003367-19 Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis not-yet-due
Reported results 2017-002241-30 A phase IIa, double-blind, randomised, placebo-controlled, dose-finding study on the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controlled ... 2020-02-27 due-trials
Ongoing 2017-003516-39 Double-blind, randomized phase III trial in adult and adolescent patients with eosinophilic esophagitis to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment wi... not-yet-due
Listed as ongoing, but also has a completion date 2017-003737-29 Double-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophilic... 2023-08-07 bad-data
Not reported 2017-004576-57 Randomised, double-blind, double-dummy, active-controlled, phase III clinical trial on the efficacy and safety of an 8-week add-on treatment with budesonide 9 mg capsules vs. budesonide 6 mg capsules ... 2022-10-03 due-trials
Ongoing 2018-002617-35 Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prev... not-yet-due
Ongoing 2018-003443-31 Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH) not-yet-due
Listed as ongoing, but also has a completion date 2019-003334-16 Randomised, double-blind, placebo-controlled, multicentre study to compare the efficacy and safety of novel 4 mg budesonide suppository in combination with oral mesalazine versus oral mesalazine monot... 2023-02-10 bad-data
Ongoing 2020-001314-37 Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets for i... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2020-001961-34 Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of RhuDex granules with placebo in the treatment of primary biliary cholangitis 2023-05-03 bad-data
Ongoing 2020-004612-97 A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet not-yet-due
Listed as ongoing, but also has a completion date 2021-001431-56 Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patients ... 2023-04-13 bad-data
Listed as ongoing, but also has a completion date 2021-002253-29 Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of ZED1227 capsules with placebo in the treatment of non-alcoholic fatty liver disease (NAFLD) with ... 2023-07-05 bad-data
Ongoing 2021-002254-86 Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at leas... not-yet-due